An Open-label, Multidose Dose-escalation Study to Understand the Safety of CRISPR Gene-editing Therapy and Its Long-Lasting Effects in DMD Patients (MUSCLE)

NCT06594094 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Duchenne Muscular Dystrophin (DMD)

Interventions

GENETIC: HG302

Sponsor

HuidaGene Therapeutics Co., Ltd.